{"product_id":"global-clinical-stage-partnering-terms-and-agreements-in-pharma-and-biotech-2016-2023","title":"Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2016-2023","description":"\u003cp\u003eGlobal Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2016-2023\u003c\/p\u003e\n\n\u003cp\u003eThe Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2016-2023 report provides a detailed understanding and analysis of how and why companies enter clinical stage partnering deals and provides details of the latest clinical agreements announced in the healthcare sector.\u003c\/p\u003e\n\n\u003cp\u003eUnderstanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.\u003c\/p\u003e\n\n\u003cp\u003eThis report contains a comprehensive listing of over 2,900 clinical stage partnering deals announced since 2016 including financial terms where available including numerous links to online deal records of actual clinical partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.\u003c\/p\u003e\n\n\u003cp\u003eThe initial chapters of this report provide an orientation of clinical stage deal making and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of why companies partner clinical stage compounds\/products.\u003c\/p\u003e\n\n\u003cp\u003eChapter 3 provides an overview of clinical stage deals strategy and deal structure including numerous case studies. Chapter 4 provides an overview of the various payment strategies used in clinical stage deals.\u003c\/p\u003e\n\n\u003cp\u003eChapter 5 provides a review of clinical stage deal making since 2016. Deals activity is reviewed by year, stage of development at signing, therapeutic area, technology type, as well as most active dealmakers.\u003c\/p\u003e\n\n\u003cp\u003eChapter 6 provides a detailed analysis of clinical stage payment terms including headline, upfront, milestone and royalty rates for phase I, phase II and phase III deals.\u003c\/p\u003e\n\n\u003cp\u003eChapter 7 provides a review of the leading clinical stage deal by headline value. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.\u003c\/p\u003e \n\n\u003cp\u003eChapter 8 provides a comprehensive listing of the top 25 most active clinical stage dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.\u003c\/p\u003e \n\n\u003cp\u003eChapter 9 provides a comprehensive and detailed review of clinical stage partnering deals signed and announced since 2016, where a contract document is available in the public domain.\u003c\/p\u003e\n\n\u003cp\u003eChapter 10 provides a comprehensive directory of clinical stage partnering deals since 2016 organized by stage of development – phase I, phase II and phase III.\u003c\/p\u003e\n\n\u003cp\u003eThe report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J\u0026amp;J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.\u003c\/p\u003e\n\n\u003cp\u003eThe report also includes numerous tables and figures that illustrate the trends and activities in clinical stage partnering and deal making since 2016.\u003c\/p\u003e\n\n\u003cp\u003eIn addition, a comprehensive appendix of all clinical stage deals since 2016 is provided organized by partnering company A-Z, deal type, therapy focus and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.\u003c\/p\u003e\n\n\u003cp\u003eIn conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of clinical stage products and compounds.\u003c\/p\u003e\n\n\u003cp\u003eKey benefits\u003c\/p\u003e\n\n\u003cp\u003eGlobal Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2016 - 2023 provides the reader with the following key benefits:\u003c\/p\u003e\n\n\u003cp\u003eIn-depth understanding of clinical stage deal trends since 2016\u003cbr\u003e\nAccess to headline, upfront, milestone and royalty data\u003cbr\u003e\nAnalysis of the structure of clinical stage agreements with numerous real life case studies\u003cbr\u003e\nInsight into the terms included in a clinical stage agreement, together with real world clause examples\u003cbr\u003e\nUnderstand the key deal terms companies have agreed in previous deals\u003cbr\u003e\nUndertake due diligence to assess suitability of your proposed deal terms for partner companies\u003c\/p\u003e\n\n\u003cp\u003eReport scope\u003c\/p\u003e\n\n\u003cp\u003eGlobal Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2016 - 2023 is intended to provide the reader with an in-depth understanding and access to clinical stage deal trends and structure of deals entered into by leading companies worldwide.\u003c\/p\u003e\n\n\u003cp\u003eGlobal Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2016 - 2023 includes:\u003c\/p\u003e\n\n\u003cp\u003eTrends in clinical stage dealmaking in the biopharma industry since 2016\u003cbr\u003e\nAnalysis of clinical stage deal structure\u003cbr\u003e\nAccess to headline, upfront, milestone and royalty data\u003cbr\u003e\nCase studies of real-life clinical stage deals\u003cbr\u003e\nAccess to over 2,900 clinical stage deals\u003cbr\u003e\nThe leading clinical stage deals by value since 2016\u003cbr\u003e\nMost active clinical stage dealmakers since 2016\u003cbr\u003e\nThe leading clinical stage partnering resources\u003c\/p\u003e\n\n\u003cp\u003eIn Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2016 - 2023, the available contracts are listed by:\u003c\/p\u003e\n\n\u003cp\u003eCompany A-Z\u003cbr\u003e\nHeadline value\u003cbr\u003e\nStage of development at signing\u003cbr\u003e\nDeal type\u003cbr\u003e\nSpecific therapy target\u003c\/p\u003e\n\n\u003cp\u003eEach deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.\u003c\/p\u003e\n\n\u003cp\u003eThe Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2016 - 2023 report provides comprehensive access to available deals and contract documents for over 2,900 clinical stage deals.\u003c\/p\u003e \n\n\u003cp\u003eAnalyzing actual contract agreements allows assessment of the following:\u003c\/p\u003e\n\n\u003cp\u003eWhat are the precise rights granted or optioned?\u003cbr\u003e\nWhat is actually granted by the agreement to the partner company?\u003cbr\u003e\nWhat exclusivity is granted?\u003cbr\u003e\nWhat is the payment structure for the deal?\u003cbr\u003e\nHow are sales and payments audited?\u003cbr\u003e\nWhat is the deal term?\u003cbr\u003e\nHow are the key terms of the agreement defined?\u003cbr\u003e\nHow are IPRs handled and owned?\u003cbr\u003e\nWho is responsible for commercialization?\u003cbr\u003e\nWho is responsible for development, supply, and manufacture?\u003cbr\u003e\nHow is confidentiality and publication managed?\u003cbr\u003e\nHow are disputes to be resolved?\u003cbr\u003e\nUnder what conditions can the deal be terminated?\u003cbr\u003e\nWhat happens when there is a change of ownership?\u003cbr\u003e\nWhat sublicensing and subcontracting provisions have been agreed?\u003cbr\u003e\nWhich boilerplate clauses does the company insist upon?\u003cbr\u003e\nWhich boilerplate clauses appear to differ from partner to partner or deal type to deal type?\u003cbr\u003e\nWhich jurisdiction does the company insist upon for agreement law?\u003c\/p\u003e\n\n\u003cp\u003ePlease Note: This product is delivered as a zip file.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"March, 2023 \/ 1900 Pages \/ MCW16228021","offer_id":47646808277298,"sku":null,"price":4794.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/global-clinical-stage-partnering-terms-and-agreements-in-pharma-and-biotech-2016-2023","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}